Madrigal Pharmaceuticals, Inc. (MDGL)

被低估

HealthcareBiotechnologyUnited States

基本面

价格

$494.22

市值

$11.64B

Yahoo Finance TradingView 新闻官网

第一部分 · 这家公司值多少

概览

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

资产负债表与流动性

营收

$1.28B

最近12个月（截至2026/6/30）

净利润

$-325M

最近12个月（截至2026/6/30）

自由现金流

$-190M

股东权益合计

$603M

负债合计

$657M

流动比率

3.20

利息覆盖率

10.24

债务/EBITDA

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

一般情形被低估

公允价值

$682.11

当前价格

$494.22

安全边际

+27.5%

公允价值区间

$648.01 - $716.22

所用估值方法之间的离散区间，并非经过统计校准的置信区间。

估算方法

分析师目标价:$682.11

现金流折现法（DCF）:数据不足，无法计算

市盈率法（P/E）:数据不足，无法计算

格雷厄姆成长公式:数据不足，无法计算

盈利能力价值（EPV）:数据不足，无法计算

合理市净率（P/B）:数据不足，无法计算

股息折现模型（戈登模型）:数据不足，无法计算

P/FFO（运营资金）:数据不足，无法计算

周期中段收益:数据不足，无法计算

市销率法（P/S）:$172.90

分析师共识:强力买入 (22B / 2H / 0S)

最近财报超预期:+23.96%

估值指标

市盈率（P/E）

ROE

-47.8%

市净率（P/B）

22.04

P/FCF

毛利率

ROIC

-29.3%

盈利能力雷达图

价值创造（经济护城河）

ROIC

-29.3%

WACC

7.9%

ROIC − WACC

-37.2 pp

ROIC 低于资本成本：公司每投入一美元都在毁灭价值。

基本面分析标准

通过（7）

Price CAGR 42.47%
Debt/Equity ratio
Current Ratio
Interest Coverage
Low reliance on intangibles
Analyst Consensus 92% Buy
Net Margin Trend -25.3% vs -54.7%

未通过（11）

EPS shows upward trend
ROIC -29.3%
P/B Ratio 22.04
Operating Margin -25.1%
Positive Free Cash Flow
Return on Tangible Assets
DCF valuation (Unknown)
ROE -56.6%
Earnings Surprise avg -90.7%
Share Dilution 5.5%
Piotroski F-Score 3/9

不可用（9）

Gross Margin NaN%
P/FCF NaN
Dividend Payout NaN%
CapEx intensity
Debt/EBITDA
Price below Graham Number
Revenue Growth 5Y (Finnhub)
PEG Ratio (need PE > 0 and growth > 0)
Earnings Quality (OCF/Net Income)

Piotroski F-评分

3/9

存在严重财务隐患

score

criteria

盈利质量

低质量：需深入审查会计处理

股权稀释

5.5%

正在发行新股，稀释所有权

机构持股

公司治理

管理团队

姓名	职位	年龄
Mr. William J. Sibold	CEO, President & Director	59
Dr. Rebecca A. Taub M.D.	Founder, Senior Scientific & Medical Advisor and Director	73
Ms. Mardi C. Dier	Executive VP & CFO	61
Ms. Shannon Kelley	Executive VP, Chief Legal Officer & Corporate Secretary	50
Ms. Carole Huntsman	Executive VP & Chief Commercial Officer	60
Dr. David Soergel M.D.	Executive VP & Chief Medical Officer	57
Mr. Mark Underwood	Executive Vice President of Business Planning & Operations	-
Ms. Rita Thakkar	Senior VP & Chief Accounting Officer	51
Mr. Ronald Filippo	Executive VP & Chief Information Officer	-
Ms. Tina E. Ventura	Chief Investor Relations Officer	-

审计风险

董事会风险

薪酬风险

股东权利风险

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。

文件

年度报告（10-K）
对公司业务、财务业绩和风险的年度概述。
提交日期：2026-02-19
查看文件
季度报告（10-Q）
最近三个月财务表现的最新情况。
提交日期：2026-07-30
查看文件
临时报告（8-K）
关于重大事件（如管理层变动或重要公告）的通知。
提交日期：2026-08-12
查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for MDGL, sourced from Markets Gazette.

5/6/2026NEUTRAL
Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call
Madrigal Pharmaceuticals Inc. held its Q1 2026 earnings call on May 6, 2026. While the transcript is available, the provided snippet does not contain specific financial results, forward-looking statements, or significant operational updates that would directly impact the company's stock valuation. Investors seeking to assess the company's performance and outlook should refer to the full earnings report and call transcript for detailed financial figures, management commentary on key business drivers, and any guidance provided for future periods. Without this detailed information, a definitive market impact cannot be determined.
3/17/2026POSITIVE
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
Madrigal Pharmaceuticals, a clinical-stage biotech focused on NASH, obesity, and metabolic diseases, has seen its stock surge by an astonishing 1,300%. This remarkable rally has been further bolstered by a significant $181 million investment, underscoring strong investor confidence in the company's therapeutic pipeline. The substantial capital infusion is expected to accelerate clinical development and research efforts, potentially bringing its innovative small-molecule therapies closer to market approval. For investors, this dual validation of strong market performance and external financial backing signals robust growth prospects.
2/23/2026NEUTRAL
Madrigal (MDGL) Q4 2025 Earnings Call Transcript
Madrigal Pharmaceuticals has released the transcript of its fourth-quarter 2025 earnings conference call. While the news itself is informational, the document is a crucial resource for investors. Analysts and shareholders can now scrutinize the management's detailed commentary on financial performance, drug pipeline progress, and the strategic outlook for the future. The question-and-answer session will be of particular interest, as it often reveals nuances and details not found in official press releases. The availability of this comprehensive documentation allows for a deeper analysis, but does not in itself provide a directional signal until its contents are fully digested by the market.

via Markets Gazette